自曝風險且收上交所監管函 中天科技(600522.SH)一字跌停
格隆匯7月22日丨中天科技(600522.SH)一字跌停報9.18元,股價創今年2月以來新低,市值281億元。7月21日晚間,在中天科技自曝高端通信業務存重大風險後,上交所向中天科技“閃電”下發監管工作函。公司昨晚發佈《關於公司重大風險的提示公吿》稱,江蘇中天科技及其下屬經營高端通信業務的控股子公司南通江東電科通信存在部分高端通信業務相關合同執行異常,截至2021年6月30日,合併口徑預付款項213,531.20萬元對應原材料供應商交付不及預期、應收賬款51,233.16萬元逾期、扣除已收到的預收款項後剩餘未交付存貨貨值110,743.46萬元,上述事項可能導致公司產生損失的風險。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.